Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Song, Byung Seop; Hong, Chae Moon; Lee, Hong Je; Kang, Sung Min; Jeong, Shin Young; Kim, Hae Won; Chae, Yee Soo; Park, Ji Young; Lee, Sang‐Woo; Ahn, Byeong‐Cheol; Lee, Jaetae

doi:10.1007/s13139-011-0081-0

Cited by 45 publications

(40 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study (10), the group with a high primary-tumor SUVmax had a significantly worse prognosis, but LN status was the most powerful prognostic factor since all patients with disease progression were LN-positive. Although the prognostic value of nodal SUVmax was not evaluated in the previous study, we found an interesting point.…”

Section: Discussionmentioning

confidence: 80%

“…Previously, we investigated the prognostic value of 18 F-FDG uptake by the primary tumor in patients with invasive ductal breast cancer (IDC). In that study, primary-tumor maximum SUV (SUVmax) exhibited a strong relationship with known prognostic parameters of breast cancer and could be used as a good surrogate marker for the prediction of progression in patients with IDC (10). Recently, a few studies have shown that 18 F-FDG uptake by LNs as well as by the primary tumor is an important prognostic factor in patients with oral cavity squamous cell carcinoma (11) and locally advanced cervical cancer (12).…”

mentioning

confidence: 98%

See 1 more Smart Citation

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

This study assessed the maximum standardized uptake value of metastatic axillary lymph nodes in patients with invasive ductal breast cancer (IDC) to determine the pretreatment prognostic value of 18 F-FDG PET/CT for disease-free survival (DFS). Methods: Sixty-five female IDC patients who had undergone pretreatment 18 F-FDG PET/CT and had pathologically confirmed axillary lymph node involvement without distant metastasis were enrolled. All patients showed complete remission after first-line treatment. To obtain nodal SUVmax, a transaxial image representing the highest 18 F-FDG uptake was carefully selected and a region of interest was manually drawn on the 18 F-FDG-accumulating lesion. Clinicopathologic parameters such as age, TNM stage, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and primary-tumor and nodal SUVmax on PET were analyzed for their usefulness in predicting recurrence. Combinatorial effects and interactions between variables that were significant by univariate analysis were examined using multivariate Cox proportional-hazards models. Results: Twelve of 65 patients (18.5%) experienced recurrence during follow-up (median follow-up, 36 mo; range, 21-57 mo). Nodal SUVmax was significantly higher in patients with recurrence than in those who were disease-free (recurrence group: 5.2 6 2.3, vs. disease-free group: 1.9 6 1.9, P , 0.0001). A receiver-operating-characteristic curve demonstrated a nodal SUVmax of 2.8 (sensitivity, 91.7%; specificity, 86.8%; area under the curve, 0.890) to be the optimal cutoff for predicting DFS. Univariate analysis revealed that T stage, N stage, estrogen receptor status, and primary-tumor and nodal SUVmax correlated significantly with DFS. Among these 5 variables, only nodal SUVmax was found to be a single determinant of DFS by multivariate analysis (hazard ratio, 31.54; 95% confidence interval, 2.66-373.39; P 5 0.0065). Conclusion: Nodal SUVmax on pretreatment 18 F-FDG PET/CT may be an independent prognostic factor for disease recurrence in patients with IDC.

show abstract

Section: Discussionmentioning

confidence: 80%

mentioning

confidence: 98%

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…PET/CT also has been suggested to have a considerable prognostic utility in various cancers [10][11][12][13]. In a previous study, primary tumor maximum SUV (pSUVmax) exhibited a strong relationship to known prognostic parameters of invasive ductal cancer (IDC) of the breast and could be used as a good surrogate marker for the prediction of progression in patients with IDC [14]. But the relationship between HIF-1a and pSUVmax was not clearly reported in IDC.…”

Section: Originalmentioning

confidence: 99%

Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT

Jeong

Jung

Cho³

et al. 2017

Nucl. Med. Rev.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mastectomy performed upon completion of NAC (eight courses) showed no pCR 1 3 controversial. Several authors have suggested that SUV in primary breast cancer [10,[96][97][98][99] or in axillary LN metastasis [34,100] could be predictive of outcome. Jo et al [99] evaluated whether preoperative SUV max of the primary tumor was associated with DFS in 508 patients with invasive ductal breast cancer, along with histological and biological factors such as tumor size, histological grade, or hormonal receptor expression status, and concluded that a high primary tumor SUV max is an independent factor associated with recurrence.…”

Section: Prognostic Valuementioning

confidence: 99%

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Kitajima

Miyoshi

2016

Jpn J Radiol

View full text Add to dashboard Cite

by malignant cells, opened a new field in clinical oncologic imaging. Recently, integrated positron emission tomography/computed tomography (PET/CT), in which a full-ringdetector clinical PET scanner and multidetector-row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session, and provides precise anatomic localization of suspicious areas of increased FDG uptake. When used in a clinical setting, FDG-PET/CT leads to a significant improvement in diagnostic accuracy and has had a considerable impact on patient management, including diagnosis, initial staging, optimization of treatment, restaging, monitoring of the response to therapy, and prognostication of various malignant tumors. We herein review the current and future roles of FDG-PET/CT in the management of breast cancer, discussing its usefulness and limitations for imaging in these patients. DiagnosisFDG-PET imaging has poor sensitivity (<50 %) for subcentimeter breast cancers [9,10]. This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].In order to improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 h after FDG injection (dual-time imaging) [4]. Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake [4]. However, dual-time Abstract Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

show abstract

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Cited by 45 publications

References 23 publications

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Contact Info

Product

Resources

About

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Cited by 45 publications

References 23 publications

18F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

18F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Contact Info

Product

Resources

About

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer

¹⁸F-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer